Therapeutic-area Dossier
Cardiology
Therapeutic-area Dossier for Cardiology (heart and circulatory medicines). Australian brands, active ingredients, PBS-listed treatments, PBAC outcomes —…
- Brand: ADEMPAS
- Brand: AGGRASTAT
- Brand: AMDARONE
- Brand: AMLODIPINE/VALSARTAN NOVARTIS
- Brand: APO-ENALAPRIL
- Brand: APO-EZETIMIBE/SIMVASTATIN
- Sponsor: Arrotex Pharmaceuticals
- Sponsor: Alphapharm
- Sponsor: GM Pharma
- Sponsor: Sandoz
What is
Cardiology Cardiology encompasses cardiovascular pharmaceuticals, with 715 brands registered in this therapeutic area.
Brands registered in
Cardiology The top registered brands in Cardiology include: — ADEMPAS — AGGRASTAT — APO-CLONIDINE — APO-ENALAPRIL — APO-FRUSEMIDE — APO-INDAPAMIDE — APO-NEBIVOLOL — APO-NIFEDIPINE XR — APO-PRAZOSIN — APO-Propranolol — ARIXTRA — ATENOLOL
Sponsor landscape
The cardiology market is served by 93 active sponsors. Key sponsors in this area include Arrotex Pharmaceuticals, Alphapharm, GM Pharma, Ipca Pharma, Sandoz, Pharmacor, Viatris and Strides Pharma Science.
PBS and regulatory activity
There are 81 brands with PBS-listed items in Cardiology, with the latest PBS schedule dated 1 May 2026. Regulatory oversight is demonstrated by 49 brands with recorded PBAC outcomes and 33 brands with AusPARs, with the most recent PBAC outcome recorded on 1 December 2025 and the latest AusPAR dated 31 January 2025.